Pfizer (NYSE:PFE) Trading Up 2% – Should You Buy?

Pfizer Inc. (NYSE:PFE) was up 2% during trading on Monday . The stock traded as high as $28.70 and last traded at $28.51. Approximately 44,692,075 shares were traded during mid-day trading, an increase of 7% from the average session volume of 41,789,922 shares. The stock had previously closed at $27.96.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong quarterly results supported the rally. Pfizer reportedly exceeded earnings expectations, while revenue growth and its updated outlook reinforced confidence in the company’s turnaround. The latest reported quarter included $0.77 in adjusted EPS versus a $0.68 consensus estimate and $15.03 billion in revenue versus $14.40 billion expected. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Depo-Provera litigation settlement removes a significant uncertainty. Pfizer reached a confidential settlement covering more than 6,000 federal lawsuits related to alleged risks from Depo-Provera. Although the financial terms were undisclosed and Pfizer admitted no liability, the agreement may reduce litigation-related uncertainty and potential future costs. Pfizer Reaches Confidential Settlement in Depo-Provera Litigation
• Positive Sentiment: Investors are focusing on oncology and vaccine growth. Padcev is leading Pfizer’s oncology expansion, while pipeline programs and potential label expansions could provide longer-term growth beyond the company’s COVID-related revenue decline. From Padcev to PF-08634404: Pfizer’s Oncology Growth Push
• Neutral Sentiment: Pfizer’s dividend appeal is attracting defensive investors. Its relatively high yield may benefit from a rotation toward cash-generating companies, although the yield also reflects investor concerns about growth and future capital allocation. 3 Stocks for Investors Who Still Believe Cash Is King
• Negative Sentiment: Unusually heavy put-option activity signals hedging or bearish speculation. Traders purchased 147,173 put options, approximately 24% above typical daily volume, suggesting some market participants are positioning for downside or protecting recent gains.
• Negative Sentiment: Longer-term performance remains a concern. Pfizer has underperformed the S&P 500 over the past year, and investors continue to weigh declining pandemic-era sales, execution risks, and whether oncology growth can offset those pressures. Is Pfizer Stock Underperforming the S&P 500?

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research note on Tuesday, June 9th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. Bank of America decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a research note on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $28.28.

Pfizer Price Performance

The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock has a 50 day simple moving average of $25.69 and a two-hundred day simple moving average of $26.31. The company has a market cap of $162.84 billion, a price-to-earnings ratio of 37.59 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.0%. Pfizer’s dividend payout ratio is presently 226.32%.

Hedge Funds Weigh In On Pfizer

Large investors have recently made changes to their positions in the stock. Brown Lisle Cummings Inc. boosted its position in shares of Pfizer by 11.6% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 74,737 shares of the biopharmaceutical company’s stock worth $1,800,000 after purchasing an additional 7,752 shares during the period. California State Teachers Retirement System boosted its position in shares of Pfizer by 2,320.6% during the second quarter. California State Teachers Retirement System now owns 217,981,455 shares of the biopharmaceutical company’s stock worth $5,248,993,000 after buying an additional 208,976,273 shares during the period. Studio Investment Management LLC grew its stake in shares of Pfizer by 16.2% in the second quarter. Studio Investment Management LLC now owns 37,694 shares of the biopharmaceutical company’s stock valued at $908,000 after buying an additional 5,249 shares in the last quarter. Henrickson Nauta Wealth Advisors Inc. acquired a new stake in shares of Pfizer in the second quarter valued at $328,000. Finally, Kintra Wealth LLC raised its holdings in shares of Pfizer by 14.8% in the 2nd quarter. Kintra Wealth LLC now owns 56,271 shares of the biopharmaceutical company’s stock valued at $1,355,000 after buying an additional 7,248 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.